A.P. Pharma, Inc. has hired a consulting practice in regulatory affairs to lead the FDA Review Process for its lead product candidate, APF530 for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. APF530 is a long-acting formulation of granisetron that uses the company’s Biochronomer drug delivery system. In March 2010, the company received a Complete Response Letter from the FDA regarding its NDA, which outlined several issues to be addressed prior to FDA appro...